Summary of UNICEF Study: A Commercial Perspective of Vaccine Study

App)eI1.\ x3

CD
-4

The major players in the vaccine industry are re-positioning themselves by dealmaking

LprIIuuIfluJI1rttLfIP1LILJntthrui JJflILiIF r uu1muHLaJ1muunJErnuuuuuI1ru*aJmu.utmlur ullimJuJurLwaJTIurImur iIiLJJiILJIHUUILIUtJ11IUUlIfT*UITS

M
ti

S mlthKflne Beecham

Merckc

Pre-90

1989: acquired Connaught Labs,
Inc.
January: Merger of lnsbitut
Pasteur and Menieux

Leodetle
1989: acquired Praxis
Biologicals.

Hoechst

--4
rC-)
C,
rm

1990
1991

June; Agreement with Via!
Re: gene therapy vaccines Pacific
joini venture with CSL

1992 Agreement with Mchigan for US
supply of OPT and rabies
June: 5KB to sell HY IB
vaccine in US
December Exclusive rights to
RIBI Immnunochemn range of
adjuvants.
September~ Agreement with
Cambridge Biotech on adjuvant
technology
April: Acquires Sachische
Senriwertce
1993 April: Supply agreement with
doekh1 for DPI

May: US paediatric vaccine
collaboration with JM~
May: European JV with iM
finalsed

February: Collaboration with
Irmmune Response
R1e: AIDS vaccine
September: Colfaboration with
~b1on Malaria
Connaught supplied with acettular
pertussis by Bliken, Osaka
June: PMSV H-110 vaccine sold by
in iiUS
May: US paediatric vaccine
collaboration with &r
May: European J.V. with M+~I
finalisedf

)
January: Coopedtat ion with~"
Sachische Serumwerke (stopij
September: Collaboration wits'
EMYon malaria (stopped)
N)
1)
Supply agreement with flfog~f
DPITc
4

Source: Corrpzany reports, Uit searches

CoD

2IO~~iOU-Z34LW

Mercer 1%. agement Consulting